"Intravenous carbamazepine (IV CBZ) is in development in the US for short-term replacement of oral
carbamazepine in adult patients with epilepsy. In June, Lundbeck received FDA Orphan drug status for
this product,which is expected to be submitted to the FDA during the first quarter of 2014." From their Q4.